CURRENTLY SOLD OUT
About this product
Product Identifiers
PublisherSpringer Berlin / Heidelberg
ISBN-103540566988
ISBN-139783540566984
eBay Product ID (ePID)4433066
Product Key Features
Number of Pages277 Pages
LanguageEnglish
Publication NameAmlodipine
Publication Year1993
SubjectPharmacology, Cardiology
TypeTextbook
AuthorWinifred G. Nayler
Subject AreaMedical
FormatTrade Paperback
Dimensions
Item Weight16.2 Oz
Item Length9.3 in
Item Width6.1 in
Additional Product Features
Intended AudienceScholarly & Professional
Dewey Edition20
Number of Volumes1 vol.
IllustratedYes
Dewey Decimal615.71
Table Of Content1. The Calcium Antagonists: Are Different Drugs Needed?.- 2. Calcium and Its Relevance to Biological Systems.- 3. Cell Membrane Transport.- 4. The Voltage-Activated, Calcium Antagonist-Sensitive Calcium Channels: Their Structure, Composition and Calcium Antagonist Binding Sites.- 5. The Chemistry of the Calcium Antagonists.- 6. Amlodipine -- A Long-Acting Second Generation Calcium Antagonist With an Unusual Binding Profile.- 7. The Pharmacokinetic Properties of Amlodipine.- 8. The Vascular Selectivity of Amlodipine.- 9. Conditions Which Affect the Pharmacokinetic Profile of Amlodipine.- 10. Calcium Antagonists and the Kidney.- 11. Calcium Antagonism and the Ischaemic Heart: Is Calcium Antagonism Relevant?.- 12. Calcium Antagonists and the Stunned Heart -- Are Vascular Selective Antagonists Protective?.- 13. Amlodipine and the Hibernating Myocardium: Could it be Beneficial?.- 14. Calcium Antagonists and the Treatment of Hypertension.- 15. The Antiatherogenic Potential of the Calcium Antagonists, Including Amlodipine.- 16. Amlodipine and the Coronary Circulation: Is it a Useful Antianginal Agent?.- 17. Calcium Antagonists and Heart Failure.- 18. The Side-Effects of Calcium Antagonist Therapy. Is Amlodipine Different?.- 19. The Future of Calcium Antagonism.- References.
Synopsis"Those who choose to increase their knowledge still further by reading ... will discover an exciting new world. " NOEL WHITTAKER, in "Making Money Made Simple" 1989. The development of calcium antagonists has recently been described as representing "one of the major advances in cardiovascular thera- peutics of the latter half of the twentieth century" (Braunwald, 1990). However, although the development of these drugs started in the mid- nineteen sixties it is only recently that their real potential has begun to be appreciated. Even now the calcium antagonist saga is not complete, since new compounds continue to appear and new therapeutic applica- tions emerge. Based on the experience gained in the clinics in which these drugs have been used recognition is being given now to the need to improve upon the prototypes of the group. Such improvement is resulting in the development and production not only of long-acting formulations of the prototypes (nifedipine, verapamil and diltiazem) but also of new calcium antagonists with improved tissue selectivity, potency and duration of action. To those of us who are interested in this field such a development is both exciting and rewarding. As far as the clinicians who prescribe these drugs are concerned the long-acting nature of some of the newer calcium antagonists should make the satisfactory management of their patients an achievable goal., "Those who choose to increase their knowledge still further by reading ... will discover an exciting new world. " NOEL WHITTAKER, in "Making Money Made Simple" 1989. The development of calcium antagonists has recently been described as representing "one of the major advances in cardiovascular thera peutics of the latter half of the twentieth century" (Braunwald, 1990). However, although the development of these drugs started in the mid nineteen sixties it is only recently that their real potential has begun to be appreciated. Even now the calcium antagonist saga is not complete, since new compounds continue to appear and new therapeutic applica tions emerge. Based on the experience gained in the clinics in which these drugs have been used recognition is being given now to the need to improve upon the prototypes of the group. Such improvement is resulting in the development and production not only of long-acting formulations of the prototypes (nifedipine, verapamil and diltiazem) but also of new calcium antagonists with improved tissue selectivity, potency and duration of action. To those of us who are interested in this field such a development is both exciting and rewarding. As far as the clinicians who prescribe these drugs are concerned the long-acting nature of some of the newer calcium antagonists should make the satisfactory management of their patients an achievable goal.
LC Classification NumberRC666-701.2
